Tuesday, November 6, 2007 :: Imaging Diagnostic Systems Expands Key Patent Coverage
Imaging Diagnostic Systems Expands Key Patent Coverage Breast Cancer Treatment May Be Activated With Laser Light Beams Fort Lauderdale, Florida, November 6, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast cancer imaging systems, announced that a patent, “Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells” was issued to IMDS by the Chinese government. “We are very pleased to have been issued this patent in China and to extend our protection in another important market,” stated Tim Hansen, IMDS Chief Executive Officer. “With this patent comes additional hope that breast cancer may someday be imaged and treated with light-activated compounds. Our current proprietary CT Laser Mammography System (CTLM®) is uniquely capable in these applications.” The Chinese patent, ZL 99 8 16608.1, joins the Australian patent 775069, issued July 2004; European patent EP01181511, issued June 2005; Hong Kong patent HK1043480, issued January 2006; and German patent DE69925869 issued May 2006. The patents, along with a previously issued Canadian patent, are equivalents of US patent 5,952,644. They protect the concept of imaging and activating a photodynamic therapy agent in an optical CT scanner, a combined diagnostic and therapeutic system. This is the second patent issued to IMDS in China. About Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth. Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. For more information, visit our website: www.imds.com As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from
expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements. Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com Media Contact: Elizabeth Williams (954) 581-9800 williams@imds.com

Monday, November 5, 2007 :: Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health Fort Lauderdale, Florida, November 5, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast cancer imaging systems, announced that CT Laser Mammography (CTLM®) results were exhibited at the 4th Congress of the World Society for Breast Health in Tianjin, China, October 18th - 21st. The Congress attracted more than 500 breast health experts from 23 different countries and offered 29 clinical and academic presentations on breast health, including epidemiology, screening, diagnosis, prevention, and the treatment of breast cancer. IMDS local representatives exhibited clinical imaging cases from international sites. Several meeting attendees visited the recent CTLM installation at the Tianjin Medical University Cancer Institute and Hospital, where clinical studies are now underway. Explained Tim Hansen, IMDS Chief Executive Officer: “Exhibiting at the Congress allowed us to support our global commercialization efforts while highlighting the research that is being conducted at the Tianjin Medical University Cancer Institute and Hospital as well as at Beijing Friendship Hospital. Having an operating CTLM system in the same city helped reinforce our messages to those seriously considering our approach. China represents a significant market; CTLM solves real clinical problems for these users and their patients.” The Congress was organized by the World Society for Breast Health, the Chinese Oncology Society and the Chinese Medical Association, along with the Tianjin Medical University Cancer Institute and Hospital, which served as the local organizer. Previous World Society for Breast Health Congresses have been held in Istanbul, Turkey; Budapest, Hungary; and Tokyo, Japan. About Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth. Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements. Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com Media Contact: Elizabeth Williams (954) 581-9800 williams@imds.com

Wednesday, September 5, 2007 :: Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System

Imaging Diagnostic Systems Installs CTLM® in Tianjin, China

Fort Lauderdale, Florida, September 5, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast cancer imaging systems, has installed a CT Laser Mammography (CTLM®) system at the Tianjin Medical University’s Cancer Institute and Hospital, the largest breast disease center in China.

Research at the Cancer Institute will be led by Professor Bao Runxian, Director of Radiology. Data will be collected under three research protocols designed to improve current methods of addressing breast cancer imaging and treatment follow-up. Professor E. Milne, MD, IMDS Director of Clinical Research will train the University doctors on CTLM adjunctive image interpretation and protocol methodologies.

The Tianjin system is the second research system installed in China. The first, at Beijing’s Friendship Hospital, enabled CTLM clinical procedures to become listed on the Regional schedule for patient payments. IMDS plans to install several more research CTLM systems in China to accelerate market adoption of the new laser breast imaging technique.

Both the incidence and the number of deaths from breast cancer has tripled in Chinese women, making it the second most common cause of death from cancer for Chinese women. Early detection may provide women with better treatment options. Sources in China report that the incidence of breast cancer in has increased by at least 27% over the past decade and 40% of the Chinese women diagnosed with breast cancer die within five years because the cancer is already very advanced when it is diagnosed.

The Cancer Institute and Hospital is planning the 4th Congress of the World Society for Breast Health, in Tianjin, October 18th through October 21st. The Congress is sponsored by the World Society for Breast Health, the China Oncology Society and the Chinese Medical Association. IDSI Beijing will present CTLM clinical findings at the meeting.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com

Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com

Tuesday, September 4, 2007 :: Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
Tuesday September 4, 9:30 am ET
FORT LAUDERDALE, Fla., Sept. 4 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) a pioneer in laser optical breast cancer imaging systems, has shipped a CT Laser Mammography (CTLM®) system to the Universiti Putra Malaysia (UPM) in Kuala Lumpur, Malaysia, the first such scanner in the country.
The CTLM system will be installed at UPM's academic facility within the jurisdiction of the Ministry of Education and will be evaluated by specialists from UPM in conjunction with specialists from Serdang Hospital in Kuala Lumpur.
An IMDS spokesperson said, "We are pleased to add Malaysia to those areas in Asia where CTLM is being considered as a possible solution for improving the diagnosis and management of breast cancer cases. UPM is very forward- looking and, we believe, focused on improving women's health services through advanced technologies."
The CTLM system is expected to be in service by Oct 1st.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com

Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com


________________________________________
Source: Imaging Diagnostic Systems, Inc.